|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
JP4732696B2
(ja)
|
2002-04-09 |
2011-07-27 |
フラメル・テクノロジー |
活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
|
|
KR20050111318A
(ko)
|
2003-01-13 |
2005-11-24 |
다이노젠 파마세우티컬스, 인코포레이티드 |
기능성 장 질환을 치료하는 방법
|
|
SI1589966T1
(sl)
*
|
2003-01-30 |
2011-06-30 |
Lek Pharmaceuticals D.D. |
Postopek čiščenja losartana
|
|
JP3874419B2
(ja)
*
|
2003-01-31 |
2007-01-31 |
三共株式会社 |
動脈硬化及び高血圧症の予防及び治療のための医薬
|
|
WO2005079752A2
(en)
*
|
2004-02-11 |
2005-09-01 |
Rubicon Research Private Limited |
Controlled release pharmaceutical compositions with improved bioavailability
|
|
US7838552B2
(en)
*
|
2004-06-04 |
2010-11-23 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
|
EP1806137A4
(en)
*
|
2004-10-29 |
2011-03-30 |
Kowa Co |
THERAPEUTIC AGENT FOR THE TREATMENT OF GLOMERULAR DISEASE
|
|
FR2884145A1
(fr)
*
|
2005-04-06 |
2006-10-13 |
Flamel Technologies Sa |
Forme pharmaceutique orale de losartan
|
|
FR2882260A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
|
|
CA2598410A1
(fr)
*
|
2005-02-21 |
2006-08-24 |
Flamel Technologies |
Forme pharmaceutique orale de losartan
|
|
WO2007001066A1
(en)
*
|
2005-06-27 |
2007-01-04 |
Daiichi Sankyo Company, Limited |
Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
|
|
DE102005031577A1
(de)
*
|
2005-07-06 |
2007-01-11 |
Bayer Healthcare Ag |
Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
|
|
AU2006329564A1
(en)
|
2005-07-11 |
2007-07-05 |
Pharmena North America Inc. |
Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
|
|
TWI399223B
(zh)
*
|
2006-09-15 |
2013-06-21 |
Daiichi Sankyo Co Ltd |
奧美沙坦酯及氨氯地平之固體劑型
|
|
KR100888131B1
(ko)
*
|
2006-10-10 |
2009-03-11 |
한올제약주식회사 |
시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
|
|
WO2009084040A1
(en)
*
|
2007-12-28 |
2009-07-09 |
Rubicon Research Private Limited |
Once a day formulation of angiotensin receptor blockers
|
|
WO2009114648A1
(en)
|
2008-03-11 |
2009-09-17 |
Depomed Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
|
US8372432B2
(en)
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
|
KR101209319B1
(ko)
*
|
2008-04-29 |
2012-12-06 |
한올바이오파마주식회사 |
안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
|
|
TW201014850A
(en)
*
|
2008-09-25 |
2010-04-16 |
Takeda Pharmaceutical |
Solid pharmaceutical composition
|
|
DE102008059206A1
(de)
|
2008-11-27 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
|
|
EP2427243A4
(en)
|
2009-05-05 |
2012-11-21 |
Vapogenix Inc |
NEW FORMULATIONS OF VOLATILE ANESTHETICS AND METHOD OF ADMINISTRATION
|
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
EP2392318A1
(en)
|
2010-05-21 |
2011-12-07 |
Laboratorios Liconsa, S.A. |
A pharmaceutical controlled release composition of losartan
|
|
JP6245983B2
(ja)
|
2010-08-11 |
2017-12-13 |
ドレクセル ユニバーシティ |
パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト
|
|
EP2648754A4
(en)
|
2010-12-07 |
2016-02-24 |
Philadelphia Health & Educatio |
METHOD OF INHIBITING CANCER METASTASES
|
|
US8476221B2
(en)
|
2011-03-18 |
2013-07-02 |
Halimed Pharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders
|
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
|
US9050335B1
(en)
|
2011-05-17 |
2015-06-09 |
Mallinckrodt Llc |
Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
|
|
AU2012345659B2
(en)
|
2011-12-02 |
2017-09-28 |
Synchroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
EP2794565B1
(en)
|
2011-12-21 |
2017-07-26 |
Novira Therapeutics Inc. |
Hepatitis b antiviral agents
|
|
WO2013167453A1
(en)
|
2012-05-07 |
2013-11-14 |
Bayer Pharma Aktiengesellschaft |
Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil
|
|
WO2014015157A2
(en)
|
2012-07-19 |
2014-01-23 |
Philadelphia Health & Education Corporation |
Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
|
|
EP3158995B1
(en)
|
2012-08-09 |
2018-05-23 |
Dynamis Therapeutics, Inc. |
Meglumine for reducing high triglyceride levels
|
|
PT2941233T
(pt)
|
2013-01-07 |
2020-11-13 |
Univ Pennsylvania |
Composições e métodos para tratar linfoma cutâneo de células t
|
|
WO2014197744A1
(en)
|
2013-06-05 |
2014-12-11 |
Synchroneuron, Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
US10117841B2
(en)
|
2013-07-02 |
2018-11-06 |
Ecoplanet Environmental Llc |
Volatile organic compound formulations having antimicrobial activity
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
US20160193155A1
(en)
|
2013-09-02 |
2016-07-07 |
Sun Pharmaceutical Industries Limited |
Pulsatile-release dosage form
|
|
US9908915B2
(en)
|
2013-11-26 |
2018-03-06 |
Yale University |
Cell-penetrating compositions and methods using same
|
|
EA031243B1
(ru)
*
|
2013-12-06 |
2018-12-28 |
Дженентек, Инк. |
Ингибиторы серин/треонинкиназ
|
|
WO2015089049A1
(en)
|
2013-12-09 |
2015-06-18 |
Thomas Jefferson University |
Novel methods of treating a neurodegenerative disease in a mammal in need thereof
|
|
WO2015157262A1
(en)
|
2014-04-07 |
2015-10-15 |
Women & Infants Hospital Of Rhode Island |
Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CA2968215A1
(en)
|
2014-08-20 |
2016-02-25 |
Yale University |
Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
|
|
US10597368B2
(en)
|
2015-05-08 |
2020-03-24 |
Brown University |
Syringolin analogues and methods of making and using same
|
|
EP3298140B1
(en)
|
2015-05-19 |
2024-04-24 |
Yale University |
Compositions for treating pathological calcification conditions, and methods using same
|
|
US10829440B2
(en)
|
2015-06-12 |
2020-11-10 |
Brown University |
Antibacterial compounds and methods of making and using same
|
|
CA2989885C
(en)
|
2015-06-30 |
2025-05-06 |
Neurad Ltd. |
NEW RESPIRATION REGULATION MODULATION COMPOUNDS AND THEIR MANUFACTURING AND USE PROCESSES
|
|
WO2017017165A1
(en)
*
|
2015-07-29 |
2017-02-02 |
Takeda Gmbh |
Pde4 inhibitor for the treatment of diabetic nephropathy
|
|
WO2017075145A1
(en)
|
2015-10-28 |
2017-05-04 |
Yale University |
Quinoline amides and methods of using same
|
|
EP3377105A4
(en)
|
2015-11-20 |
2019-04-24 |
Yale University |
COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH
|
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
|
EP3448369B1
(en)
|
2016-04-29 |
2025-06-25 |
The Regents of The University of Colorado, A Body Corporate |
Inhibition or degradation of hdac11 for treating obesity, hyperlipidemia, type ii diabetes, metabolic syndrome or insulin resistance, for promoting weight loss, and/or ameliorating or preventing weight gain
|
|
US20210330599A1
(en)
|
2016-08-01 |
2021-10-28 |
University Of Rochester |
Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
|
|
US11390859B2
(en)
|
2016-08-05 |
2022-07-19 |
Yale University |
Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
|
|
EP3506983B1
(en)
|
2016-09-01 |
2021-08-25 |
Mebias Discovery, Inc. |
Substituted urea-derivatives for the treatment of pain
|
|
JP7113009B2
(ja)
|
2016-11-07 |
2022-08-04 |
アービュタス バイオファーマ コーポレイション |
置換ピリジノン含有三環式化合物およびそれを使用する方法
|
|
US10941126B2
(en)
|
2017-01-19 |
2021-03-09 |
Temple University-Of The Commonwealth System Of Higher Education |
Bridged bicycloalkyl-substituted aminothiazoles and their methods of use
|
|
MA49014A
(fr)
|
2017-03-21 |
2020-02-05 |
Arbutus Biopharma Corp |
Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
|
|
CN110753546B
(zh)
|
2017-04-17 |
2023-11-10 |
耶鲁大学 |
治疗或预防急性肺损伤的化合物、组合物和方法
|
|
CA3071345A1
(en)
|
2017-07-28 |
2019-01-31 |
Yale University |
Anticancer drugs and methods of making and using same
|
|
CN111527103A
(zh)
|
2017-09-08 |
2020-08-11 |
科罗拉多大学董事会,法人团体 |
用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法
|
|
WO2019104316A1
(en)
|
2017-11-27 |
2019-05-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compounds, compositions, and methods for treating and/or preventing periodontal disease
|
|
US12514818B2
(en)
|
2017-12-18 |
2026-01-06 |
Tris Pharma, Inc. |
Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
|
AU2018388577B2
(en)
|
2017-12-18 |
2024-06-06 |
Tris Pharma, Inc. |
Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
|
|
US11337920B2
(en)
|
2017-12-18 |
2022-05-24 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
|
|
US11666546B2
(en)
|
2017-12-18 |
2023-06-06 |
Tris Pharma, Inc |
GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
|
WO2019125184A1
(en)
|
2017-12-19 |
2019-06-27 |
Auckland Uniservices Limited |
Use of biomarker in cancer therapy
|
|
AU2019212241A1
(en)
|
2018-01-24 |
2020-08-13 |
The Rockefeller University |
Antibacterial compounds, compositions thereof, and methods using same
|
|
JP7572006B2
(ja)
|
2018-05-25 |
2024-10-23 |
テンプル ユニヴァーシティ － オブ ザ コモンウェルス システム オブ ハイアー エデュケーション |
抗アミロイドモノクローナル抗体を使用した細菌バイオフィルムの根絶
|
|
KR20210015892A
(ko)
|
2018-05-29 |
2021-02-10 |
세르시 테라퓨틱스 인코포레이티드 |
통증 치료를 위한 화합물, 이를 포함하는 조성물 및 이를 사용하는 방법
|
|
TWI869058B
(zh)
|
2018-07-27 |
2025-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
CN112703009B
(zh)
|
2018-08-17 |
2024-06-11 |
宾夕法尼亚大学董事会 |
治疗急性肺损伤的组合物和方法
|
|
MX2021003653A
(es)
|
2018-10-11 |
2021-06-23 |
Sanifit Therapeutics S A |
Inositol fosfatos para el tratamiento de calcificacion ectopica.
|
|
US12458601B2
(en)
|
2018-10-19 |
2025-11-04 |
Temple University-Of The Commonwealth System Of Higher Education |
Tamper-resistant drug dosage forms and methods of making and use thereof
|
|
TWI827760B
(zh)
|
2018-12-12 |
2024-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
WO2020157362A1
(en)
|
2019-01-30 |
2020-08-06 |
Sanifit Therapeutics, S.A. |
Inositol phosphate compounds for use in increasing tissular perfusion
|
|
US20200246317A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
|
|
WO2020159565A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
|
|
AU2020271901A1
(en)
|
2019-04-12 |
2021-11-04 |
Sdg, Inc. |
Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
|
|
US11471508B2
(en)
|
2019-05-09 |
2022-10-18 |
The Feinstein Institutes For Medical Research |
HMGB1 antagonist treatment of diabetic peripheral neuropathy
|
|
EP3983391A4
(en)
|
2019-06-12 |
2023-06-28 |
The Wistar Institute |
Acetyl-coa synthetase 2 (acss2) inhibitors and methods using same
|
|
US11555010B2
(en)
|
2019-07-25 |
2023-01-17 |
Brown University |
Diamide antimicrobial agents
|
|
EP3818983A1
(en)
|
2019-11-11 |
2021-05-12 |
Sanifit Therapeutics S.A. |
Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
|
|
WO2021127456A1
(en)
|
2019-12-19 |
2021-06-24 |
Rain Therapeutics Inc. |
Methods of inhibiting epidermal growth factor receptor proteins
|
|
EP4162036A1
(en)
|
2020-06-09 |
2023-04-12 |
Inozyme Pharma, Inc. |
Soluble enpp1 or enpp3 proteins and uses thereof
|
|
WO2022067165A1
(en)
|
2020-09-28 |
2022-03-31 |
Yale University |
Selective agonists of 5-ht2a receptor and methods of use
|
|
EP4015494A1
(en)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Processes for the preparation of soluble salts of inositol phosphates
|
|
EP4036097A1
(en)
|
2021-01-29 |
2022-08-03 |
Sanifit Therapeutics S.A. |
Ip4-4,6 substituted derivative compounds
|
|
WO2023004291A1
(en)
|
2021-07-19 |
2023-01-26 |
Baylor College Of Medicine |
Coronavirus main protease inhibitors and methods using same
|
|
TW202412815A
(zh)
|
2022-07-29 |
2024-04-01 |
西班牙商薩尼菲特治療公司 |
Ip5經取代化合物
|
|
AU2023313374A1
(en)
|
2022-07-29 |
2025-02-13 |
Vifor (International) Ltd. |
Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
|
|
WO2024052895A1
(en)
|
2022-09-06 |
2024-03-14 |
Hadasit Medical Research Services And Development Ltd |
Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders
|
|
CN121038779A
(zh)
|
2023-02-03 |
2025-11-28 |
特瑞斯制药公司 |
每晚一次的低钠羟丁酸盐组合物
|
|
KR20260053367A
(ko)
|
2023-08-14 |
2026-04-21 |
뉴림 파머슈티칼스(1991) 리미티드 |
Gal475 조성물 및 그의 사용 방법
|
|
WO2025162971A1
(en)
|
2024-01-31 |
2025-08-07 |
Sanifit Therapeutics, S.A. |
Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
|
|
WO2025217094A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
|
|
WO2025217096A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
|
|
WO2025217379A1
(en)
|
2024-04-10 |
2025-10-16 |
University Of Rochester |
Drug treatment for macular degeneration
|
|
WO2026050206A1
(en)
|
2024-08-27 |
2026-03-05 |
Ironwood Pharmaceuticals, Inc. |
Combinations of glp-1 and guanylate cyclase c (gc-c) receptor agonists
|
|
WO2026136387A1
(en)
|
2024-12-16 |
2026-06-25 |
University Of Rochester |
Drug treatment for macular degeneration
|